User:Mr. Ibrahem/Everolimus
 | |
 | |
| Clinical data | |
|---|---|
| Pronunciation | Everolimus /ˌɛvəˈroʊləməs/ |
| Trade names | Afinitor, Zortress, others |
| Other names | 42-O-(2-hydroxyethyl)rapamycin, RAD001 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a609032 |
| License data |
|
| Pregnancy category |
|
| Routes of administration | By mouth |
| Drug class | mTOR inhibitor, kinase inhibitor[2] |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | ~30 hours[3] |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C53H83NO14 |
| Molar mass | 958.240 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Everolimus is a medication used to prevent rejection after an organ transplant and to treat certain types of cancer.[2] This includes after kidney, heart, and liver transplant.[4] It may be used for breast, kidney, and neuroendocrine tumors.[5] It is taken by mouth.[2]
Common side effects include mouth inflammation, respiratory tract infection, tiredness, vomiting, and diarrhea.[2] Other side effects may include hair loss, low white blood cells, bleeding, kidney problems, blood clotting, and heart failure.[4] It is likely that use during pregnancy would harm the baby.[6] It is a derivative of sirolimus and works similarly; by blocking mammalian target of rapamycin (mTOR).[5][7]
Everolimus was approved for medical use in the United States and Europe in 2009.[2][5] It is available as a generic medication.[4] It is on the World Health Organization's List of Essential Medicines.[8] In the United Kingdom a month of treatment post transplant costs about £450 while for certain types of cancer can be £2,900 as of 2020.[4] A similar amount to prevent transplant rejection costs about 450 USD in the United States as of 2021.[9] A generic version was approved in 2021 in the USA.[10]
References[edit]
- ^ a b Use During Pregnancy and Breastfeeding
- ^ a b c d e "Everolimus Monograph for Professionals". Drugs.com. Archived from the original on 17 April 2021. Retrieved 23 July 2021.
- ^ Formica RN, Lorber KM, Friedman AL, Bia MJ, Lakkis F, Smith JD, Lorber MI (March 2004). "The evolving experience using everolimus in clinical transplantation". Transplantation Proceedings. 36 (2 Suppl): 495S–499S. doi:10.1016/j.transproceed.2004.01.015. PMID 15041395.
- ^ a b c d BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 1034. ISBN 978-0-85711-369-6.
{{cite book}}: CS1 maint: date format (link) - ^ a b c "Afinitor". Archived from the original on 8 April 2021. Retrieved 23 July 2021.
- ^ "Everolimus Use During Pregnancy". Drugs.com. Archived from the original on 17 April 2021. Retrieved 23 July 2021.
- ^ Wheeler, Derek S.; Wong, Hector R. (2007). Pediatric Critical Care Medicine: Basic Science And Clinical Evidence. Springer Science & Business Media. p. 1391. ISBN 978-1-84628-463-2. Archived from the original on 2021-08-28. Retrieved 2021-07-23.
- ^ World Health Organization (2021). World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. hdl:10665/345533. WHO/MHP/HPS/EML/2021.02.
- ^ "Everolimus Prices, Coupons & Savings Tips - GoodRx". GoodRx. Retrieved 23 July 2021.
- ^ Research, Center for Drug Evaluation and (10 February 2022). "2021 First Generic Drug Approvals". FDA. Archived from the original on 21 June 2022. Retrieved 22 October 2022.